HUDSON, N.Y., May 04, 2017 -- Taconic Biosciences, global leader in genetically engineered mouse models and associated services and the only commercial provider of germ-free mice, announced it has added Germ Free BALB/c mice to its microbiome portfolio. The new product expands Taconic’s existing collection of germ-free animal models, which includes C57BL/6 (Black 6) and Swiss Webster mice.
The BALB/c inbred strain is commonly used for antibody production and vaccine efficacy studies. It is also widely used in adoptive transfer studies such as adoptive transfer colitis models and syngeneic tumor studies for immuno-oncology research. Taconic offers Germ Free BALB/c mice as an off-the-shelf product, with study cohorts available for immediate worldwide delivery.
“BALB/c have been an unmet need in terms of germ-free strain availability,” said Dr. Alexander Maue, Taconic’s portfolio director for microbiome products and services. “The BALB/c inbred strain displays Th2-biased immune responses, as opposed to the Th1 bias in C57BL/6 mice, opening a whole new range of studies. Availability of germ-free mice in quantities relevant for drug discovery accelerates development of microbiome-focused therapeutics.”
Germ-free mice, also referred to as axenic mice, contain no microflora. These mice can be associated with specific human or mouse flora, or mono-associated with particular bacteria. Germ-free mice are the ideal substrate for performing fecal microbiota transplants (FMT), a service provided by Taconic. Following FMT, Taconic also offers husbandry services to accommodate studies of all sizes and lengths including options for isolators and state-of-the-art individually ventilated cages (IVCs).
Study of the microbiome has become a prime focus of drug discovery, as evidence mounts demonstrating the connection between a person’s flora and their health. Science magazine named the microbiome their breakthrough of the year in both 2011 and 2013 and the microbiome topped Cleveland Clinic’s medical innovations list for 2016. Taconic’s microbiome platform provides key products and services to study this connection.
To learn more about Taconic’s microbiome solutions, visit Taconic.com/microbiome or contact us at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or at [email protected].
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact: Kelly Owen Grover Director of Marketing Communications (518) 697-3824 [email protected]


DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Google Secures Pentagon AI Deal for Classified Projects
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 



